Latest Listings And Ipos News

Kaili Resources has officially confirmed a change of control with Mr Jianzhong Yang now holding over 60% of shares, alongside a significant board reshuffle. The company remains focused on advancing its rare earth elements exploration in South Australia.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Astron Corporation Limited is set to redomicile from Hong Kong to Australia through a scheme of arrangement, creating a new Australian parent company, Aus NewCo. This move aims to align the corporate structure with its Australian assets and simplify shareholder voting.

Harmoney Corp has delivered a record FY25 performance, exceeding profit expectations and boosting its FY26 profit forecast by 20%, driven by strong loan growth and its advanced Stellare 2.0 platform.

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.

Straker Ltd reported a 10% revenue decline in FY25 but achieved record gross margins and adjusted EBITDA, underscoring its strategic shift to AI-driven language services and expanding IBM partnership.

WAM Strategic Value Limited has declared an increased fully franked dividend following an 8.6% rise in its investment portfolio for FY2025, showcasing resilience amid market volatility.

WAM Strategic Value reported a near 50% drop in net profit for FY2025 but maintained its fully franked dividend, supported by an 8.6% portfolio gain that outperformed market downturns.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Vital Metals Limited has voluntarily suspended trading of its shares pending a key announcement on a capital raise, following an ASX price and volume query.